between HIV-2 and HIV-1 infections, respectively.
Two types of human immunodeficiency virus (HIV) have been identified; they are designated HIV type 1 (HIV-1) and HIV-2. While HIV-2 is mainly restricted to West Africa or to individuals originating from that area or having contact with individuals from West Africa, the spread of HIV-1 continues worldwide (1, 4, 6, 7, 9, 11, 12, 16, 17, 19) .
Control of HIV has been shown to be difficult. Sexual transmission of HIV and spread of the virus through illicit drug abuse can be influenced to some extent by educational programs (3, 8) .
An additional important tool that can be used to reduce the spread of HIV is the early and reliable recognition of the HIV infection by sensitive tests (15) . The anti-HIV 1 and 2 test has been shown to reduce significantly the risk of HIV infection by blood and blood products (2, 15, 18) . The test is also able to identify HIV-infected persons, allowing them to adjust their behaviors. Thus, sensitive and reliable anti-HIV 1 and 2 tests also contribute significantly to a reduction in the spread of HIV infection (2, 15, 18) .
Here we report on a newly developed anti-HIV 1 and 2 test which also allows the serological discrimination between HIV-1 and HIV-2. In addition, components of the test can be used to monitor HIV infection and thereby add to the staging of the HIV disease.
MATERIALS AND METHODS
Methods. Five different antigens were selected for use in recognizing antibodies to HIV-1 and HIV-2. p24 is a recombinant protein that was generated as described previously (13) ; all other antigens were peptides and were derived from gp32/36 (HIV-2) and gp4l and gpl20 (HIV-1). Recombinant antigens and peptides were labelled as described previously (10) .
Test concept. Streptavidin-coated tubes were manufactured as described previously (5, 10) . Biotin-labelled antigens were allowed to bind to streptavidin for 60 min. After removal of unbound antigen, 20 ,ul of serum was added to the tube and was allowed to react with the antigens for 60 min. Specifically bound immunoglobulins were recognized by an antibody against immunoglobulin G obtained from sheep and labelled with peroxidase as described previously (14) .
The peroxidase that was bound to the tube was visualized by using ABTS substrate and was read with a photometer at a wavelength of 405 nm. Tests were performed on automated systems (ES 22, ES 300, and ES 600; Boehringer Mannheim GmbH, Mannheim, Germany). 16 samples had a single gp160 band, 4 samples had a single p55 band, and 3 samples had both p24 and p55 bands on Western blotting. None of these serum samples was positive for HIV antigen, as assessed by a commercial enzyme-linked immunosorbentassay (Abbott). All patients were followed for at least 6 months; none of them converted to anti-HIV status with a positive Western blot result.
The latter two categories of sera were selected and designated "tricky samples." RESULTS Optimization of the anti-HIV 1 and 2 test. A total of 200 anti-HIV-1-and 50 anti-HIV-2-positive serum samples as well as 600 serum samples from healthy humans were used to optimize the anti-HIV 1 and 2 test.
Individual HIV-1 and HIV-2 antigens were diluted in incubation buffer, and the anti-HIV test was performed as described above. The individual antigen concentration that revealed 95% of the maximum extinction was considered the optimum antigen concentration (data not shown). The actual antigen concentration was reduced by 20% in order to avoid antigen excess in the tube. Different sample volumes were also evaluated. The sensitivity of the test was identical irrespective of the sample volume (10, 20, or (Table   1 ).
In addition, the intra-and interassay precisions were determined. The intraassay precision was assessed by using one negative and two positive serum samples. In order to analyze the interassay precision, five serum samples (one negative and four positive serum samples) were tested in seven consecutive runs. Precision in all experiments varied between 3.9 and 6.9%. (Fig. 2) . The data indicate that components of the anti-HIV 1 and 2 test can be used to discriminate between HIV-1 and HIV-2 infections if the anti-HIV 1 and 2 test reads positive.
DISCUSSION
This report described a new anti-HIV 1 and 2 test. The test achieved specificity and sensitivity similar to those of the tests used as references in the present trial (2) . In some experiments, it appeared that the test was even superior to the reference tests. This became evident in selected serum samples from individuals from Africa and Asia, but also when serum samples from individuals who seroconverted were tested. In the seroconversions described here, one anti-HIV test became positive only when the Western blot analysis already showed a nearly complete Western blot pattern. This is unusual, because, in general, enzyme-linked immunoassays detect seroconversion several weeks earlier than Western blot assays do. The variable performance of anti-HIV 1 and 2 tests may depend predominantly on the antigens that are selected for use and the variable antibody responses of the individuals. Also, the level of the initial immunoglobulin M response may have an impact on the early outcome of an anti-HIV test.
The specificity of the anti-HIV 1 and 2 test appeared to be lower when blood samples from healthy donors were tested. Whether this is in fact the case is open to question. In fact, it has been demonstrated that the anti-HIV 1 and 2 test is highly sensitive; sera from some of the blood donors may have been weakly positive, but anti-HIV-1 or anti-HIV-2 was not recognized by other enzyme-linked immunosorbent assays or Western blotting. Whether this consideration remains an option cannot be defined because sequential serum samples were not available for testing. This would have allowed an estimate of whether some of the falsepositive sera in fact represented early seroconversion probes.
An additional important advantage of the anti-HIV 1 and 2 test is that it is run on a highly automated system. This automation limits to a minimum the mistakes that can be made by human hands; in addition, it significantly reduces the risk of mixing samples, which is of high significance in anti-HIV testing. It also has improved precision and thereby Thus, the data that we obtained suggest that the discrimination assay can be used to select samples for Western blot analysis and to reassess HIV results by Western blotting with respect to cross-reactivity between HIV-1 and HIV-2.
In summary, the new anti-HIV 1 and 2 test is highly suited for anti-HIV screening. The flexibility of the test concept allows discrimination between HIV-1 and HIV-2; thus, the newly developed anti-HIV 1 and 2 test has the additional features of being able to diagnose HIV infection and may contribute to a reduction in the spread of this deadly disease (2, 15, 18) .
